The estimated Net Worth of Phillip Md Et Al Frost is at least $295 Миллион dollars as of 2 April 2020. Phillip Frost owns over 500,000 units of Opko Health Inc stock worth over $293,703,843 and over the last 21 years he sold OPK stock worth over $0. In addition, he makes $1,405,200 as Chairman of the Board и Chief Executive Officer at Opko Health Inc.
Sign up
Phillip Frost OPK stock SEC Form 4 insiders trading
Phillip has made over 31 trades of the Opko Health Inc stock since 2003, according to the Form 4 filled with the SEC. Most recently he bought 500,000 units of OPK stock worth $580,000 on 2 April 2020.
The largest trade he's ever made was buying 11,111,111 units of Opko Health Inc stock on 11 March 2005 worth over $5,000,000. On average, Phillip trades about 327,402 units every 39 days since 2003. As of 2 April 2020 he still owns at least 188,271,694 units of Opko Health Inc stock.
You can see the complete history of Phillip Frost stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Phillip Frost biography
Dr. Phillip Frost M.D. serves as Chairman of the Board, Chief Executive Officer of the Company. Dr. Frost has been the Chief Executive Officer of the Company and Chairman of the Board since March 2007. Dr. Frost serves as a director for Castle Brands (NYSE American:ROX), a developer and marketer of premium brand spirits, and Cocrystal Pharma, Inc. (NASDAQ GM:COCP), a publicly traded biotechnology company developing new treatments for viral diseases. He serves as a member of the Board of Trustees of the University of Miami, the Skolkovo Foundation Scientific Advisory Council in Russia, the Shanghai Institute for Advanced Immunochemical Studies in China, and The Florida Council of 100 and as a Trustee of each of the Miami Jewish Home for the Aged and the Mount Sinai Medical Center. He serves as Chairman of Temple Emanu-El, Governor of Tel Aviv University and is a member of the Executive Committee of The Phillip and Patricia Frost Museum of Science. Dr. Frost served as a director of Ladenburg Thalmann Financial Services Inc. (“Ladenburg Thalmann”) (NYSE American:LTS), an investment banking, asset management, and securities brokerage firm providing services through its principal operating subsidiary, Ladenburg Thalmann & Co. Inc., from 2004 to 2018 and had served as its Chairman from July 2006 until September 2018, a director of Teva Pharmaceutical Industries, Limited, or Teva (NYSE:TEVA) from January 2006 until February 2015 and had served as Chairman of the Board of Teva from March 2010 until December 2014. Dr. Frost previously served as Vice Chairman of Cogint, Inc., now known as Fluent, Inc. (NASDAQ:FLNT), and as a director for Sevion Therapeutics, Inc. prior to its merger with Eloxx Pharmaceuticals, Inc., and TransEnterix, Inc., (NYSE American:TRXC). Dr. Frost had served as Chairman of the Board of Directors and Chief Executive Officer of IVAX Corporation (“IVAX”) from 1987 until its acquisition by Teva in January 2006. Dr. Frost was Chairman of the Board of Directors of Key Pharmaceuticals, Inc.
What is the salary of Phillip Frost?
As the Chairman of the Board и Chief Executive Officer of Opko Health Inc, the total compensation of Phillip Frost at Opko Health Inc is $1,405,200. There are no executives at Opko Health Inc getting paid more.
How old is Phillip Frost?
Phillip Frost is 83, he's been the Chairman of the Board и Chief Executive Officer of Opko Health Inc since 2007. There are 2 older and 19 younger executives at Opko Health Inc. The oldest executive at Opko Health Inc is John Paganelli, 85, who is the Independent Director.
What's Phillip Frost's mailing address?
Phillip's mailing address filed with the SEC is OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI, FL, 33137.
Insiders trading at Opko Health Inc
Over the last 18 years, insiders at Opko Health Inc have traded over $862,245 worth of Opko Health Inc stock and bought 128,867,460 units worth $425,265,065 . The most active insiders traders include Phillip Md Et Al Frost Neva..., Phillip Md Et Al Frost Gamm... и Phillip Md Et Al Frost Gamm.... On average, Opko Health Inc executives and independent directors trade stock every 4 days with the average trade being worth of $142,696. The most recent stock trade was executed by Phillip Md Et Al Frost Gamm... on 23 May 2024, trading 100,000 units of OPK stock currently worth $127,000.
What does Opko Health Inc do?
opko health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. our diagnostics business includes bioreference laboratories, the nation's third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4kscore® prostate cancer test and the claros® 1 in office immunoassay platform. our pharmaceutical business features rayaldee, an fda approved treatment for shpt in stage 3-4 ckd patients with vitamin d insufficiency (launched in november 2016), varubitm for chemotherapy induced nausea and vomiting (oral formulation launched by partner tesaro and iv formulation pending fda approval), opk88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in phase 2 clinical trials, among the new class of glp-1 glucagon receptor dual agonists, and opk88003, a selective androgen receptor modulator for benig
What does Opko Health Inc's logo look like?
Complete history of Phillip Frost stock trades at Opko Health Inc, Northrop Grumman, Osaic Services, Cocrystal Pharma Inc и Osaic Services
Opko Health Inc executives and stock owners
Opko Health Inc executives and other stock owners filed with the SEC include:
-
Phillip Frost,
Chairman of the Board, Chief Executive Officer -
Jane Hsiao,
Vice Chairman of the Board, Chief Technical Officer -
Steven Rubin,
Executive Vice President - Administration, Director -
Adam E. Logal,
Sr. VP & CFO -
Dr. Phillip Frost Ph.D.,
Chairman & CEO -
Adam Logal,
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer -
Dr. Jane H. Hsiao M.B.A., MBA, Ph.D.,
Vice Chairman & Chief Technical Officer -
Steven D. Rubin Esq., J.D.,
Exec. VP of Admin. & Director -
Richard Pfenniger,
Independent Director -
John Paganelli,
Independent Director -
Richard Krasno,
Independent Director -
Richard Lerner,
Independent Director -
Robert Fishel,
Independent Director -
Alice Yu,
Independent Director -
Yvonne Briggs,
Investor Relations -
Anthony Japour,
Independent Director -
Geoff Monk,
President of BioReference Laboratories -
Tony Cruz,
Chief Executive Officer, Transition Therapeutics, Inc -
Charles Bishop,
Chief Executive Officer of OPKO Renal -
Jon Cohen,
Director, Executive Chairman of BioReference Laboratories -
Dr. David Okrongly Ph.D.,
Pres of OPKO Diagnostics -
Jane Pine Wood Esq., J.D.,
Chief Legal Officer of Bio-Reference Laboratories -
Dr. Akhtar Ashfaq,
Sr. VP of Clinical R&D and Medical Affairs -
James DeMarco,
Sr. VP of Pharmaceutical Sales -
Dr. Arie Gutman,
Pres of API -
Alexis Borisy,
Director -
Phillip Md Et Al Frost Gamm...,
CEO & Chairman -
Gary J. Nabel,
Chief Innovation Officer -
Phillip Md Et Al Frost Neva...,
CEO & Chairman -
Phillip Md Et Al Frost,
CEO & Chairman -
Roger Md Medel,
-
Prem A Lachman,
-
Gamma Investment Trust Frost,
10% owner -
Subbarao V Uppaluri,
Senior VP- CFO -
Thomas E Beier,
Director -
Robert A Baron,
Director -
Michael Reich,
Director -
David A Eichler,
Director -
Dmitry Kolosov,
Director -
Md Pascal J Goldschmidt,,
Director -
Elias A. Zerhouni,
Vice Chairman and President